<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>tumor microenvironment &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/tumor-microenvironment/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 26 Jan 2026 07:38:12 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>tumor microenvironment &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Neutrophils: Key Players in Cancer and Immunotherapy</title>
		<link>https://bioengineer.org/neutrophils-key-players-in-cancer-and-immunotherapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 26 Jan 2026 07:37:47 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: `Tumor-associated neutrophils]]></category>
		<category><![CDATA[Neutrophil dynamics]]></category>
		<category><![CDATA[Spatiotemporal dynamics]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tumor-associated neutrophils]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neutrophils-key-players-in-cancer-and-immunotherapy/</guid>

					<description><![CDATA[In recent years, the intricate interplay between the immune system and tumor development has captured the attention of researchers and clinicians alike. A groundbreaking study led by a team of scientists, including notable authors Chu, Ma, and Li, has shed new light on the spatiotemporal dynamics of tumor-associated neutrophils (TANs), offering insights into their role [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320950</post-id>	</item>
		<item>
		<title>Enhancing CAR-T Cells: Targeting Tumor Characteristics</title>
		<link>https://bioengineer.org/enhancing-car-t-cells-targeting-tumor-characteristics/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 26 Jan 2026 02:45:49 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[and overcoming limitations]]></category>
		<category><![CDATA[and personalized approaches]]></category>
		<category><![CDATA[Based on the content focusing on next-gen CAR-T cells targeting tumor-specific features]]></category>
		<category><![CDATA[Based on the content focusing on next-generation CAR-T cell design]]></category>
		<category><![CDATA[Combination cancer therapies]]></category>
		<category><![CDATA[combination immunotherapy]]></category>
		<category><![CDATA[CRISPR gene-editing]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Next-generation CAR-T]]></category>
		<category><![CDATA[here are 5 suitable tags: **Next-generation CAR-T cells]]></category>
		<category><![CDATA[microenvironment adaptation]]></category>
		<category><![CDATA[personalized cancer immunotherapy]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tumor microenvironment targeting]]></category>
		<category><![CDATA[tumor targeting]]></category>
		<guid isPermaLink="false">https://bioengineer.org/enhancing-car-t-cells-targeting-tumor-characteristics/</guid>

					<description><![CDATA[In a groundbreaking advancement in cancer immunotherapy, researchers have unveiled the next-generation design of CAR-T cells that strategically leverage unique tumor features to enhance therapeutic efficacy. This innovative approach promises to significantly improve patient outcomes in the ongoing battle against resilient malignancies. By capitalizing on tumor heterogeneity and microenvironmental cues, this study paves the way [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320878</post-id>	</item>
		<item>
		<title>Inhibiting ITGB2 Axis Suppresses Melanoma Growth</title>
		<link>https://bioengineer.org/inhibiting-itgb2-axis-suppresses-melanoma-growth/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 25 Jan 2026 11:20:44 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[and therapeutic implications]]></category>
		<category><![CDATA[Based on the content highlighting ITGB2's role in melanoma progression]]></category>
		<category><![CDATA[Cancer therapeutics** * **ITGB2 inhibition:** Ana araştırma konusu ve terapötik hedef. * **Melanoma targeted therapy:** Çalışmanın odaklandığı hastalık (melanoma) ve tedavi yaklaşımı (he]]></category>
		<category><![CDATA[drug resistance]]></category>
		<category><![CDATA[here are 5 appropriate tags: **Melanoma Therapy]]></category>
		<category><![CDATA[İçerik analizi sonucunda en uygun 5 etiket: **ITGB2 inhibition]]></category>
		<category><![CDATA[inhibition strategies]]></category>
		<category><![CDATA[ITGB2 Inhibition]]></category>
		<category><![CDATA[Melanoma drug resistance]]></category>
		<category><![CDATA[Melanoma targeted therapy]]></category>
		<category><![CDATA[Metastasis]]></category>
		<category><![CDATA[microenvironment interactions]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/inhibiting-itgb2-axis-suppresses-melanoma-growth/</guid>

					<description><![CDATA[Recent research has unveiled a crucial pathway in melanoma progression, identifying the tumor cell-intrinsic ITGB2 axis as a promising target for therapeutic intervention. This groundbreaking study, led by Rasbach et al., emphasizes the importance of exploring intrinsic cellular mechanisms to combat one of the most aggressive forms of skin cancer. The team discovered that melanoma [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320679</post-id>	</item>
		<item>
		<title>GPNMB+ Macrophages Promote Vascular Fibrosis in Glioblastoma</title>
		<link>https://bioengineer.org/gpnmb-macrophages-promote-vascular-fibrosis-in-glioblastoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 25 Jan 2026 06:18:49 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[COL6A3 fibroblasts]]></category>
		<category><![CDATA[Glioblastoma]]></category>
		<category><![CDATA[GPNMB macrophages]]></category>
		<category><![CDATA[GPNMB+ makrofajlar]]></category>
		<category><![CDATA[hücresel etkileşim mekanizmaları]]></category>
		<category><![CDATA[İşte bu içerik için en uygun 5 etiket (Türkçe ve virgülle ayrılmış): **Glioblastoma mikroçevresi]]></category>
		<category><![CDATA[klinik çıkarımlar** **Açıklama:** 1. **Glioblastoma mikroçevresi:**]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[vascular fibrosis]]></category>
		<category><![CDATA[vasküler fibroz]]></category>
		<guid isPermaLink="false">https://bioengineer.org/gpnmb-macrophages-promote-vascular-fibrosis-in-glioblastoma/</guid>

					<description><![CDATA[In a groundbreaking study, a research team led by Du, Long, and Li has unveiled the intricate relationship between spatially-reprogrammed GPNMB+ macrophages and COL6A3+ fibroblasts in the context of vascular fibrosis associated with glioblastoma. This research, featured in the prestigious journal “Genome Medicine,” sheds light on the cellular interactions that exacerbate tumor progression in one [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320607</post-id>	</item>
		<item>
		<title>Fibroblast-Derived SOD3 Fuels Lung Cancer Spread</title>
		<link>https://bioengineer.org/fibroblast-derived-sod3-fuels-lung-cancer-spread/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 18:11:49 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer-associated fibroblasts]]></category>
		<category><![CDATA[Kanser araştırması makalesinin içeriğine ve anahtar kelimelerine dayanarak en uygun 5 etiket: **SOD3 role in metastasis]]></category>
		<category><![CDATA[Lung adenocarcinoma metastasis]]></category>
		<category><![CDATA[Lymphangiogenesis]]></category>
		<category><![CDATA[Lymphangiogenesis in cancer]]></category>
		<category><![CDATA[SOD3]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tumor microenvironment interactions** * **SOD3 role in metastasis:** Makalenin ana bulgusu SOD3'ün metastazdaki kritik rolünü vurgular. * **Cancer-associated fibroblasts]]></category>
		<guid isPermaLink="false">https://bioengineer.org/fibroblast-derived-sod3-fuels-lung-cancer-spread/</guid>

					<description><![CDATA[In a groundbreaking study, researchers have elucidated the role of cancer-associated fibroblasts (CAFs) in promoting metastasis in lung adenocarcinoma through the secretion of superoxide dismutase 3 (SOD3). This revelation offers new insights into the intricate relationships between tumor microenvironments and cancer progression, significantly expanding our understanding of metastasis mechanisms. The malignant behaviors typical of lung [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320400</post-id>	</item>
		<item>
		<title>HDAC6 Drives Metastasis and Immunosuppression in Lung Cancer</title>
		<link>https://bioengineer.org/hdac6-drives-metastasis-and-immunosuppression-in-lung-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 24 Jan 2026 05:14:46 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy** **Açıklama:** 1. **HDAC6:** Makalenin temel odağı ve araştırılan ana molekül. 2. **Lung cancer metastasis:** Çalışmanın inceledi]]></category>
		<category><![CDATA[HDAC6]]></category>
		<category><![CDATA[immunosuppression]]></category>
		<category><![CDATA[Lung cancer metastasis]]></category>
		<category><![CDATA[Makalenin içeriğine ve anahtar kelimelerine göre en uygun 5 etiket: **HDAC6]]></category>
		<category><![CDATA[Metastasis]]></category>
		<category><![CDATA[small-cell lung cancer]]></category>
		<category><![CDATA[TGF-β/SMAD signaling]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/hdac6-drives-metastasis-and-immunosuppression-in-lung-cancer/</guid>

					<description><![CDATA[In the realm of oncological research, the intricate mechanisms behind cancer metastasis and immune evasion are crucial questions that scientists endeavor to unravel. A recent groundbreaking study conducted by Jiang, Yu, Wang, and their collaborators sheds light on the role of HDAC6, a prominent histone deacetylase, in small cell lung cancer (SCLC). This study opens [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">320166</post-id>	</item>
		<item>
		<title>Unlocking Treatment-Resistant Cervical Cancers Through Proteogenomics</title>
		<link>https://bioengineer.org/unlocking-treatment-resistant-cervical-cancers-through-proteogenomics/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 19:07:47 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cervical cancer]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **treatment resistance]]></category>
		<category><![CDATA[Makalenin içeriği ve anahtar kelimeleri dikkate alınarak oluşturulan 5 uygun etiket: **Treatment-resistant cervical cancer]]></category>
		<category><![CDATA[Molecular targets in oncology]]></category>
		<category><![CDATA[Personalized cancer therapy** * **Treatment-resistant cervical cancer:** Makalenin temel odağı tedaviye dirençli serviks kanseri alt tipleri. * **Proteogenomics:** Çalışmanın]]></category>
		<category><![CDATA[Proteogenomics]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/unlocking-treatment-resistant-cervical-cancers-through-proteogenomics/</guid>

					<description><![CDATA[The relentless pursuit of better therapeutic strategies for treatment-resistant subtypes in locally advanced cervical cancers has garnered significant attention within the scientific community. In a groundbreaking study led by Hyeon et al., researchers undertook an extensive proteogenomic characterization of these aggressive cancer types, aiming to uncover the underlying molecular and cellular mechanisms that contribute to [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319963</post-id>	</item>
		<item>
		<title>Unraveling Small-Cell Lung Cancer: A Multi-Omic Approach</title>
		<link>https://bioengineer.org/unraveling-small-cell-lung-cancer-a-multi-omic-approach/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 23 Jan 2026 04:10:43 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[biomarker discovery]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[multi-omic profiling]]></category>
		<category><![CDATA[personalized medicine]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[small-cell lung cancer]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/unraveling-small-cell-lung-cancer-a-multi-omic-approach/</guid>

					<description><![CDATA[In a groundbreaking study, researchers have conducted a comprehensive multi-omic profiling of small-cell lung cancer (SCLC), revealing crucial insights into its heterogeneity, microenvironment, and biomarker landscape. This innovative approach combines genomic, transcriptomic, proteomic, and metabolomic analyses, providing a holistic understanding of one of the most aggressive forms of lung cancer. The findings not only shed [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319634</post-id>	</item>
		<item>
		<title>Framework Reveals Tumor Metabolic Subtypes Through Single-Cell Data</title>
		<link>https://bioengineer.org/framework-reveals-tumor-metabolic-subtypes-through-single-cell-data/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 22:57:47 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[hesaplamalı biyoloji]]></category>
		<category><![CDATA[İşte başlık ve içerik için 5 uygun etiket: **cancer metabolism]]></category>
		<category><![CDATA[Kişiselleştirilmiş Tıp]]></category>
		<category><![CDATA[metabolic subtypes]]></category>
		<category><![CDATA[Metabolik alt türler]]></category>
		<category><![CDATA[single-cell RNA sequencing]]></category>
		<category><![CDATA[Tek Hücre Analizi]]></category>
		<category><![CDATA[therapeutic targets** **Açıklama:** 1. **cancer metabolism:** Makalenin temel odağı tümörlerdeki metabolik süreçlerdir. 2. **tumor microenvironment (tümör mikroçevresi):** Çalışma]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tümör mikroçevresi]]></category>
		<guid isPermaLink="false">https://bioengineer.org/framework-reveals-tumor-metabolic-subtypes-through-single-cell-data/</guid>

					<description><![CDATA[In the realm of cancer research, the intricate interplay of cellular microenvironments and metabolic processes has long been a focus for scientists aiming to decipher the complexities of tumor development and progression. A recent groundbreaking study conducted by a team of researchers led by K. Tang, Y. Han, and D. Sun, has introduced a novel [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319523</post-id>	</item>
		<item>
		<title>Decoding Ageing Tumor Microenvironment’s Genetic and Epigenetic Factors</title>
		<link>https://bioengineer.org/decoding-ageing-tumor-microenvironments-genetic-and-epigenetic-factors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 22 Jan 2026 13:17:50 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[Cancer Development **Seçilen Etiketlerin Açıklaması:** 1. **Aging:** Makalenin temel odağı yaşlanmanın kanser gelişimi üzerindeki etkisidir. 2. **Tumor Microenvironment:** Yazı]]></category>
		<category><![CDATA[Cellular Senescence]]></category>
		<category><![CDATA[epigenetics]]></category>
		<category><![CDATA[Epigenetics in Aging]]></category>
		<category><![CDATA[Immunosenescence** * **Aging and Cancer:** Makalenin ana teması yaşlanma ile kanser riski ve gelişimi arasındaki karmaşık ilişki. * **Tumor Microenvironment:** İçerik]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket: **Aging and Cancer]]></category>
		<category><![CDATA[Senescence]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[tümörün çevresindeki bu karmaşık ortamın (immün]]></category>
		<category><![CDATA[yaşlanan tümör mikro]]></category>
		<guid isPermaLink="false">https://bioengineer.org/decoding-ageing-tumor-microenvironments-genetic-and-epigenetic-factors/</guid>

					<description><![CDATA[As we navigate through life, our bodies continuously accumulate somatic mutations that lurk beneath the surface, quietly building a foundation for potential cancer development. Research reveals that these mutations, which affect key oncogenes and tumor suppressor genes, are not exclusive to older individuals. Instead, they begin their journey from early life and progressively increase in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319298</post-id>	</item>
		<item>
		<title>Unraveling Epigenetic Control of T Cell Exhaustion in Cancer</title>
		<link>https://bioengineer.org/unraveling-epigenetic-control-of-t-cell-exhaustion-in-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 21:06:48 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer immunotherapy]]></category>
		<category><![CDATA[Cancer immunotherapy advancements]]></category>
		<category><![CDATA[Combination therapies** **Açıklama:** 1. **T cell exhaustion:** Makalenin ana konusu ve temel araştırma alanı. 2. **Epigenetic regulation:** Makalenin özellikle vurguladığı]]></category>
		<category><![CDATA[Combination therapy strategies]]></category>
		<category><![CDATA[epigenetic regulation]]></category>
		<category><![CDATA[Epigenetic regulation of T cells]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: **T cell exhaustion]]></category>
		<category><![CDATA[T hücre tükenmesini]]></category>
		<category><![CDATA[T-cell exhaustion mechanisms]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[tumor microenvironment immunosuppression]]></category>
		<guid isPermaLink="false">https://bioengineer.org/unraveling-epigenetic-control-of-t-cell-exhaustion-in-cancer/</guid>

					<description><![CDATA[Recent advancements in cancer treatment have highlighted the remarkable potential of T cell-based immunotherapy strategies, which include immune checkpoint blockade (ICB) and chimeric antigen receptor (CAR) T cells. These innovative approaches have undoubtedly transformed the landscape of cancer care, offering new avenues for treatment. Despite their success in numerous cases, there remains a significant proportion [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319150</post-id>	</item>
		<item>
		<title>Targeting Notch Signaling in Tumor Microenvironments</title>
		<link>https://bioengineer.org/targeting-notch-signaling-in-tumor-microenvironments/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 21:00:45 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[angiogenesis and immune evasion]]></category>
		<category><![CDATA[Angiogenesis** **Kısaca Seçim Nedenleri:** 1. **Notch signaling:** Makalenin ana konusu ve temel biyolojik süreç. 2. **Tumor microenvironment (TME):** Notch sinyalinin et]]></category>
		<category><![CDATA[cancer progression]]></category>
		<category><![CDATA[cancer therapeutic targets]]></category>
		<category><![CDATA[İşte içerik için uygun 5 etiket (virgülle ayrılmış): **Notch signaling]]></category>
		<category><![CDATA[Notch signaling in oncology]]></category>
		<category><![CDATA[stromal cell modulation]]></category>
		<category><![CDATA[Targeted therapeutics]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tumor microenvironment interactions]]></category>
		<guid isPermaLink="false">https://bioengineer.org/targeting-notch-signaling-in-tumor-microenvironments/</guid>

					<description><![CDATA[Notch signaling is an intricate cellular communication pathway, pivotal in various biological processes, including cell differentiation, proliferation, and apoptosis. Recent research has illuminated its profound implications within the tumor microenvironment, indicating a significant correlation between Notch signaling and cancer progression. The complexities of this signaling pathway have garnered attention, revealing potential therapeutic targets that could [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319147</post-id>	</item>
		<item>
		<title>Neutrophil Extracellular Traps: Hidden Players in Cancer</title>
		<link>https://bioengineer.org/neutrophil-extracellular-traps-hidden-players-in-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 16:04:36 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cancer metastasis]]></category>
		<category><![CDATA[Cancer Therapy Resistance** **Açıklama:** 1. **NETosis:** Makalenin temel konusu olan nötrofillerin bu spesifik ölüm ve tuzak oluşturma sürecini doğrudan hedef alır. 2.]]></category>
		<category><![CDATA[İçeriğe göre en uygun 5 etiket: **NETosis in cancer]]></category>
		<category><![CDATA[Immunosuppression in Cancer]]></category>
		<category><![CDATA[Immunosuppression in cancer** * **NETosis in cancer:** Makalenin ana konusu ve NET'lerin oluşum mekanizması vurgulanıyor. * **Tumor microenvironment (TIME):** NET'lerin etkilerinin gösterildiği ba]]></category>
		<category><![CDATA[İşte içerikle tam uyumlu 5 etiket: **NETosis]]></category>
		<category><![CDATA[Neutrophil extracellular traps]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neutrophil-extracellular-traps-hidden-players-in-cancer/</guid>

					<description><![CDATA[Recent research has shed light on the complex interactions within the tumor immune microenvironment (TIME), particularly the role of neutrophils in cancer progression. Neutrophils, which are essential components of the innate immune system, have been observed to engage in a process known as NETosis. This process results in the release of neutrophil extracellular traps (NETs), [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">319020</post-id>	</item>
		<item>
		<title>MLK Regulates Tumor Growth and Blood Vessel Formation</title>
		<link>https://bioengineer.org/mlk-regulates-tumor-growth-and-blood-vessel-formation/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 13:45:44 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Angiogenesis]]></category>
		<category><![CDATA[Cancer Therapeutic Targets** * **MLK Signaling:** Makalenin ana konusu olan MLK'nin sinyal yolaklarındaki rolünü doğrudan yansıtır. * **Cancer Angiogenesis:** Makalede vurgulanan tümör damarlanmas]]></category>
		<category><![CDATA[cancer therapeutics]]></category>
		<category><![CDATA[İşte içeriğe uygun 5 etiket: **MLK Signaling]]></category>
		<category><![CDATA[Kinase Inhibitors]]></category>
		<category><![CDATA[Makalenin içeriğine ve anahtar kelimelerine dayanarak en uygun 5 etiket: **MLK signaling]]></category>
		<category><![CDATA[Molecular oncology** * **MLK signaling:** Makalenin tam merkezinde MLK'nin sinyal iletim yolundaki rolü var. * **Tumor angiogenesis:** MLK'nin tümör büyümesi ve özell]]></category>
		<category><![CDATA[Tumor angiogenesis]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/mlk-regulates-tumor-growth-and-blood-vessel-formation/</guid>

					<description><![CDATA[In the realm of cancer research, a pivotal study has shed light on the role of mixed lineage kinase (MLK) in tumor development and angiogenesis, broadening our understanding of the complex biological processes underlying cancer progression. Conducted by a team of researchers led by Kant, S., this research takes a close look at the molecular [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318943</post-id>	</item>
		<item>
		<title>Harnessing Macropinocytosis: A Novel Cancer Therapy Approach</title>
		<link>https://bioengineer.org/harnessing-macropinocytosis-a-novel-cancer-therapy-approach/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 11:03:42 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Besin teminli tümör direnci]]></category>
		<category><![CDATA[cancer therapy]]></category>
		<category><![CDATA[Kanser metabolik terapileri]]></category>
		<category><![CDATA[Makropinocytosis]]></category>
		<category><![CDATA[Makropinocytosis hedefleme]]></category>
		<category><![CDATA[Metuozis tabanlı tedaviler]]></category>
		<category><![CDATA[nutrient scavenging]]></category>
		<category><![CDATA[Onkojenik sinyal yolları]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/harnessing-macropinocytosis-a-novel-cancer-therapy-approach/</guid>

					<description><![CDATA[In the intricate world of cellular biology, macropinocytosis stands out as a remarkable process. This form of endocytosis allows cells to internalize large volumes of extracellular fluid, along with a wide array of solutes. Characterized by the dynamic ruffling of the plasma membrane, macropinocytosis not only enables nutrient acquisition but also plays a pivotal role [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318863</post-id>	</item>
		<item>
		<title>Inhibitory Glutamatergic Feedback Targets Brain Tumors</title>
		<link>https://bioengineer.org/inhibitory-glutamatergic-feedback-targets-brain-tumors/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 10:39:37 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[brain tumor microenvironment]]></category>
		<category><![CDATA[Brain tumor therapy]]></category>
		<category><![CDATA[Glutamate signaling]]></category>
		<category><![CDATA[glutamate signaling inhibition]]></category>
		<category><![CDATA[İşte 5 uygun etiket: `Inhibitory glutamatergic feedback]]></category>
		<category><![CDATA[Neuro-oncology]]></category>
		<category><![CDATA[neurochemical modulation in oncology]]></category>
		<category><![CDATA[precision neuro-oncology]]></category>
		<category><![CDATA[synaptic regulation of tumors]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/inhibitory-glutamatergic-feedback-targets-brain-tumors/</guid>

					<description><![CDATA[In a groundbreaking advancement poised to revolutionize the treatment landscape of brain tumors, researchers have unveiled a novel therapeutic strategy centered on inhibitory glutamatergic feedback mechanisms. This pioneering approach delves into the intricate neurochemical dialogues within the tumor microenvironment, illuminating a pathway by which modulating glutamate signaling can attenuate malignant growth and improve patient outcomes. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318848</post-id>	</item>
		<item>
		<title>STAMBP Fuels Colorectal Cancer by Boosting CXCR4</title>
		<link>https://bioengineer.org/stambp-fuels-colorectal-cancer-by-boosting-cxcr4/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 10:02:33 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[colorectal cancer progression]]></category>
		<category><![CDATA[Deubiquitination in cancer]]></category>
		<category><![CDATA[deubiquitination mechanisms]]></category>
		<category><![CDATA[Myeloid-derived suppressor cells]]></category>
		<category><![CDATA[STAMBP-CXCR4 axis]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[tumor microenvironment immunosuppression]]></category>
		<guid isPermaLink="false">https://bioengineer.org/stambp-fuels-colorectal-cancer-by-boosting-cxcr4/</guid>

					<description><![CDATA[Colorectal cancer (CRC) remains a formidable adversary in global oncology, ranking among the top three causes of cancer-related mortality worldwide. Despite advances in diagnostic and therapeutic strategies, the intricate molecular mechanisms that facilitate CRC progression continue to elude comprehensive understanding. A newly published study breaks ground by unearthing the multifaceted role of STAMBP, a deubiquitinase [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318833</post-id>	</item>
		<item>
		<title>Vessels in Liver Cancer: A Unique Metastatic Route</title>
		<link>https://bioengineer.org/vessels-in-liver-cancer-a-unique-metastatic-route/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 20 Jan 2026 08:39:07 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Cancer vasculature]]></category>
		<category><![CDATA[Diagnostic Biomarkers]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[Metastatic pathways]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/vessels-in-liver-cancer-a-unique-metastatic-route/</guid>

					<description><![CDATA[A recent study published in J Transl Med has brought to light a groundbreaking finding in the realm of hepatocellular carcinoma (HCC), a type of liver cancer that has been notoriously difficult to diagnose and treat effectively. The authors, Zhu, Wang, and Cao, alongside their research team, have focused on a previously unexplored aspect of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318797</post-id>	</item>
		<item>
		<title>Cholangiocarcinoma 2026: Current Landscape and Future Priorities</title>
		<link>https://bioengineer.org/cholangiocarcinoma-2026-current-landscape-and-future-priorities/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 20:08:33 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[başlıkta ve içerikte sürekli vurgulanıyor. 2. **Tumor Microenvironment (Tümör Mikroçevresi):]]></category>
		<category><![CDATA[Cancer-associated fibroblasts]]></category>
		<category><![CDATA[Cancer-Associated Fibroblasts (CAFs)]]></category>
		<category><![CDATA[Extracellular Matrix (ECM) Remodeling]]></category>
		<category><![CDATA[extracellular matrix remodeling]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[Immunotherapy** **Açıklama:** 1. **Cholangiocarcinoma:** Makalenin ana konusu]]></category>
		<category><![CDATA[İşte 5 adet uygun etiket: **Cholangiocarcinoma]]></category>
		<category><![CDATA[İşte 5 uygun etiket: **Cholangiocarcinoma]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tumor Microenvironment (TME)]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cholangiocarcinoma-2026-current-landscape-and-future-priorities/</guid>

					<description><![CDATA[Cholangiocarcinoma (CCA) is an aggressive malignancy originating from the biliary epithelium, and its complex tumor microenvironment (TME) plays a crucial role in the disease’s progression and therapeutic resistance. Recent insights into the unique characteristics of the CCA TME have illuminated the intricate interactions between tumor cells, stromal elements, and immune components. These interactions not only [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318541</post-id>	</item>
		<item>
		<title>Neuro Gene Signatures Forecast DLBCL Prognosis and Regulation</title>
		<link>https://bioengineer.org/neuro-gene-signatures-forecast-dlbcl-prognosis-and-regulation/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 12:49:34 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer neuroscience]]></category>
		<category><![CDATA[Cancer neuroscience** **Açıklama:** 1. **DLBCL prognosis:** Çalışmanın temel odağı olan hastalık (Diffüz Büyük B-Hücreli Lenfoma) ve ana hedefi (prognoz tah]]></category>
		<category><![CDATA[DLBCL prognosis]]></category>
		<category><![CDATA[İşte 5 uygun etiket (virgülle ayrılmış): **DLBCL prognosis]]></category>
		<category><![CDATA[Neuro gene signatures]]></category>
		<category><![CDATA[Neuro-related gene signatures]]></category>
		<category><![CDATA[TRPV2]]></category>
		<category><![CDATA[TRPV2 in cancer]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<category><![CDATA[Tumor microenvironment regulation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neuro-gene-signatures-forecast-dlbcl-prognosis-and-regulation/</guid>

					<description><![CDATA[In a groundbreaking study published in the journal “Annals of Hematology,” researchers from around the globe have unveiled significant insights into the prognosis of diffuse large B-cell lymphoma (DLBCL). DLBCL is a common and aggressive form of non-Hodgkin lymphoma, characterized by the rapid proliferation of B-cells in lymphatic tissues. The complexity of this malignancy lies [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318332</post-id>	</item>
	</channel>
</rss>
